ORZORA: OS Results With Maintenance Olaparib in Platinum-Sensitive Relapsed Ovarian Cancer With a BRCA Mutation or Other HRR Mutation

In the ORZORA trial, maintenance olaparib showed similar OS outcomes in patients with platinum-sensitive relapsed ovarian cancer regardless of whether patients had a germline or a somatic BRCA mutation or a non-BRCA HRR mutation.